Connection
Kian Behbakht to Cost-Benefit Analysis
This is a "connection" page, showing publications Kian Behbakht has written about Cost-Benefit Analysis.
|
|
Connection Strength |
|
|
|
|
|
0.508 |
|
|
|
-
Behbakht K, Cohn DE, Straughn JM. Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer. Gynecol Oncol. 2018 10; 151(1):4-5.
Score: 0.508